Osimertinib in the Treatment of Non-Small-Cell Lung Cancer: Design, Development and Place in Therapy

Lung Cancer: Targets and Therapy - New Zealand
doi 10.2147/lctt.s119644
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

Informa UK Limited

Related search

Brigatinib for ALK-positive Metastatic Non-Small-Cell Lung Cancer: Design, Development and Place in Therapy

Drug Design, Development and Therapy
Drug DiscoveryPharmacologyPharmaceutical Science
2019English

Targeting HER2 Aberrations in Non-Small Cell Lung Cancer With Osimertinib

Clinical Cancer Research
Cancer ResearchOncology
2018English

Osimertinib in Patients With Advanced Epidermal Growth Factor Receptor T790M Mutation-Positive Non-Small Cell Lung Cancer: Rationale, Evidence and Place in Therapy

Therapeutic Advances in Medical Oncology
Oncology
2017English

Osimertinib (AZD9291) Increases Radio‑sensitivity in EGFR T790M Non‑small Cell Lung Cancer

Oncology Reports
MedicineCancer ResearchOncology
2018English

Targeted Therapy for the Treatment of Advanced Non-Small Cell Lung Cancer

Chest
CardiologyCritical CareCardiovascular MedicineIntensive Care MedicinePulmonaryRespiratory Medicine
2005English

Bevacizumab in the Treatment of Non-Small-Cell Lung Cancer

Oncogene
Cancer ResearchGeneticsMolecular Biology
2007English

Innovations in the Treatment of Non-Small Cell Lung Cancer

English

Individualization of Treatment in Non-Small Cell Lung Cancer

F1000 Medicine Reports
2009English

Erlotinib in Non-Small Cell Lung Cancer Treatment: Current Status and Future Development

Oncologist
Cancer ResearchMedicineOncology
2007English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy